BD to Offer Euro-denominated Senior Unsecured Notes

FRANKLIN LAKES, N.J., Dec. 1, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) announced today its intention to offer senior unsecured notes under a shelf registration statement on Form S-3 (File No. 333-206020) on file with the Securities and Exchange Commission. The interest rate, the maturity dates and other key terms of the offering are to be determined at the time of pricing.

BD intends to use the net proceeds from the offering, together with other sources of liquidity, to fund the purchase price and accrued and unpaid interest for BD's notes validly tendered and accepted for payment in one of the cash tender offers previously announced by BD.

Citigroup Global Markets Limited, Barclays Bank PLC and BNP Paribas are acting as joint book-running managers for the offering. A shelf registration statement relating to the offering was filed with the Securities and Exchange Commission on July 31, 2015. A preliminary prospectus supplement and the accompanying base prospectus relating to the offering have been filed with the Securities and Exchange Commission and are available on its website, http://www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the offering may also be obtained from:

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About BD

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 40,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.

Contact:  
Kristen Cardillo, Communications – 201-847-5657
Monique Dolecki, Investor Relations – 201-847-5378

SOURCE BD (Becton, Dickinson and Company)

Related Links

http://www.bd.com